Streetbeat News

Price Targets

ARHS

Morgan Stanley analyst Simeon Gutman has maintained an Equal-Weight rating on Arhaus (NASDAQ:ARHS) and lowered the price target from $12 to $9.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:39 pm

SNDR

Susquehanna analyst Bascome Majors has downgraded Schneider National (NYSE:SNDR) from Positive to Neutral and lowered the price target from $32 to $23.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:24 pm

ALPN

Morgan Stanley analyst Michael Ulz has maintained an Overweight rating on Alpine Immune Sciences (NASDAQ:ALPN) and raised the price target from $17 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:23 pm

ALNY

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Alnylam Pharmaceuticals and raised the price target from $175 to $183.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:22 pm

FTNT

Stifel analyst Adam Borg has downgraded Fortinet (NASDAQ:FTNT) from Buy to Hold and lowered the price target from $69 to $52.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:21 pm

GOLF

Morgan Stanley analyst Megan Alexander has maintained an Equal-Weight rating on Acushnet Hldgs (NYSE:GOLF) and raised the price target from $59 to $60.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:20 pm

SIX

B. Riley Securities has upgraded Six Flags Entertainment (NYSE:SIX) from Neutral to Buy and raised the price target from $24 to $30.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:17 pm

ROST

Gordon Haskett analyst Chuck Grom has upgraded Ross Stores (NASDAQ:ROST) from Accumulate to Buy and announced a $135 price target.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:16 pm

FUN

Citigroup analyst James Hardiman has upgraded Cedar Fair (NYSE:FUN) from Neutral to Buy and raised the price target from $40 to $46.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:13 pm

ACAD

Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and raised the price target from $30 to $31.

Portfolio Pulse from Benzinga Newsdesk

November 03, 2023 | 12:12 pm